Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Aromatase Inhibitor in HR+ Breast Cancer
NCT03874325Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2019
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in breast cancer (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Rate of Modified Preoperative Endocrine Prognostic Index (mPEPI) Score of 0 at 6 months. Started Apr 2019; status: terminated.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03874325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874325.